First month, then every month
Semaglutide, tirzepatide and retatrutide each get the same treatment: a starting-dose figure for month one, then an all-doses figure for the months after it. The page states it twice — once in prose, once in the product cards — and its FAQ repeats it a third time.
That is the disclosure a reader needs and rarely gets. An introductory rate presented alone is not a price; it is the first of twelve payments, eleven of which are larger.
We have stored the ongoing figures as the price for all three and recorded the first-month rates as introductory offers, so no comparison on this site can quote the low number as if it recurred.
A molecule with nothing approved behind it
The third lane is retatrutide. Unlike semaglutide and tirzepatide, it has no FDA-approved finished product of any kind — there is no approved drug it is a compounded version of. Its ongoing price is also stated as a range set by dose, so the upper end of the bill is not published.
The practice is unusually direct about what compounding means: its own copy describes the product as containing the same active ingredient as a brand-name medication, in those words, rather than implying it obliquely.
Named people, unnamed company
Its physician and its physician assistant are named on the priced page and again on its about page with biographies. That is a real prescriber disclosure.
The company is not. We read the about page and the privacy policy in full and ran a widened corporate-suffix pattern over both; the only matches were clinician credentials — precisely the false positive that a naive entity check reports as a company. We are recording that we could not confirm an entity rather than naming one we could not verify. A site-wide discount banner also rides the priced page.
MD Total Wellness's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $299/mothe ONGOING rate. The page reads "Semaglutide – first month starting dose $199/mo, then all doses $299/mo", so $199 is a one-month figure and this is the steady state | September 2026source |
| Tirzepatide (compounded) | $399/mothe ongoing rate; the first month at the starting dose is $299/mo | September 2026source |
| Retatrutide (compounded) | $399/mothe bottom of an ongoing range: the page reads "Retatrutide $349 First Month Starting Dose then $399-$599/mo depending on dose". This molecule has no FDA-approved finished product at all | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 198 providers reviewed here are paid partners today; the other 194 are not. See how this works.
See MD Total Wellness's current price →Good fit if
- Readers who want to know the second-month price before paying the first.
- Buyers who want the prescribing clinicians named and looked up.
- People in Orange County who prefer an in-person practice to a national platform.
- Anyone comparing three molecules priced by the same seller on one page.
Look elsewhere if
- Readers who need to know which company they are contracting with.
- Buyers considering retatrutide, whose ongoing price is a range and which has no approved finished product behind it.
- Anyone who needs a compounding pharmacy named or a service-area list.
- People who would be caught out by a discount banner changing the first amount charged.
How this review was verified
- Re-read the priced page, the about page and the privacy policy on 7 September 2026, comparing requested to effective URLs and running a nonsense path against the host in the same run, which returned a 404.
- Stored the ongoing figure as the price for each molecule and recorded the first-month rate as an introductory offer, so the two cannot be confused in any comparison here.
- Ran a widened corporate-suffix pattern — including Co., Company, Ltd, LLP, PLLC, PC, PA and Corp — across both legal pages, proved first against a page known to name a company. Every match was a clinician credential, read in context and rejected; no entity is claimed.
- Recorded the retatrutide ongoing figure as the bottom of a stated range, with the range written into the qualifier.
- Screened the brand against FDA's live warning-letter datatable with a positive control and a nonsense negative control in the same invocation; three word matches came back, each was read, and none is this practice.